Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 1383481-11-5 | MDL No. : | MFCD24387377 |
Formula : | C6H4ClN3 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | FLCAFSOTMLXPPX-UHFFFAOYSA-N |
M.W : | 153.57 | Pubchem ID : | 67980259 |
Synonyms : |
|
Num. heavy atoms : | 10 |
Num. arom. heavy atoms : | 9 |
Fraction Csp3 : | 0.0 |
Num. rotatable bonds : | 0 |
Num. H-bond acceptors : | 2.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 38.0 |
TPSA : | 30.19 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.56 cm/s |
Log Po/w (iLOGP) : | 1.65 |
Log Po/w (XLOGP3) : | 0.95 |
Log Po/w (WLOGP) : | 1.38 |
Log Po/w (MLOGP) : | 1.18 |
Log Po/w (SILICOS-IT) : | 1.16 |
Consensus Log Po/w : | 1.27 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.06 |
Solubility : | 1.35 mg/ml ; 0.00878 mol/l |
Class : | Soluble |
Log S (Ali) : | -1.17 |
Solubility : | 10.4 mg/ml ; 0.0675 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -2.31 |
Solubility : | 0.747 mg/ml ; 0.00486 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.77 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
![]() |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
59% | at 100℃; for 16 h; | A solution of 5-chloropyridazin-3-amine (14.4 g, 111 mmol) and chloroacetaldehyde (81 mL, 556 mmol) in 2-propanol (150 mL) was heated at 100 °C for 16 h. The mixture was cooled to room temperature and concentrated. The residue was added water (400 mL) and washed with EtOAc (3x500 mL). The aqueous layer was taken to pH 8 with saturated NaHCO3 solution and was extracted with EtOAc (3x50mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated. The material was purified via column chromatography (40percent EtOAc/PE) to obtain 7-chloroimidazo[1,2-b]pyridazine (10.2, 59percent yield) as a brown solid. ‘HNMR:(400MHz, CDC13) ö 8.27 (s, 1H), 7.96 (s, 2H), 7.78 (s, 1H); LCMS 154.3 (M+H). |
[ 6775-78-6 ]
6-Chloroimidazo[1,2-b]pyridazine
Similarity: 0.79
[ 40972-42-7 ]
3,6-Dichloroimidazo[1,2-b]pyridazine
Similarity: 0.74
[ 137384-48-6 ]
6-Chloro-3-methylimidazo[1,2-b]pyridazine
Similarity: 0.73
[ 14793-00-1 ]
6-Chloro-2-methylimidazo[1,2-b]pyridazine
Similarity: 0.72
[ 166176-45-0 ]
6-Chloroimidazo[1,2-b]pyridazin-3-amine
Similarity: 0.70
[ 6653-96-9 ]
Imidazo[1,2-b]pyridazin-6-amine
Similarity: 0.81
[ 6775-78-6 ]
6-Chloroimidazo[1,2-b]pyridazine
Similarity: 0.79
[ 1159977-65-7 ]
6-Bromoimidazo[1,2-b]pyridazine
Similarity: 0.76